(Stroke. 1996;27:527-535.)
© 1996 American Heart Association, Inc.
Articles |
From Eli Lilly and Company, CNS and Cardiovascular Divisions, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Ind.
Correspondence to Dr James A. Clemens, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.
| Abstract |
|---|
|
|
|---|
Methods Immunohistochemistry was performed in sections through the dorsal hippocampus in rats subjected to 30 minutes of four-vessel occlusion. PLA2 was localized with the use of a highly selective antiserum. Double immunofluorescent localization was performed to colocalize cPLA2 with various glial cell types. cPLA2 levels were also measured by enzymatic assay and Western blot analysis.
Results A marked induction of cPLA2 was observed in activated microglia and astrocytes in the CA1 hippocampal region at 72 hours after ischemia. Only a subset of astrocytes and microglia were immunoreactive for cPLA2. Twenty-four hours after ischemia, numerous cPLA2 immunoreactive astrocytes were observed. Western blot analysis of hippocampal homogenates at 72 hours after ischemia showed induction of a 100-kD band that comigrated with purified human cPLA2, and a threefold induction in cPLA2 activity was demonstrated by enzymatic assay.
Conclusions These results indicate that both reactive astrocytes and microglia contain elevated levels of cPLA2. Induction of cPLA2 was confined to areas of neurodegeneration and likely precedes its onset. The results suggest that reactive glia may play a role in the pathophysiology of delayed neuronal death after transient global forebrain ischemia.
Key Words: astrocytes cerebral ischemia, global occlusion phospholipids rats
| Introduction |
|---|
|
|
|---|
Several different forms of PLA2 exist. Two types of mammalian PLA2 have recently been purified, cloned, and sequenced, namely the 14-kD sPLA218 19 and the 85-kD cPLA2.20 21 22 23 Although sPLA2 and cPLA2 perform the same catalytic function, their structural and biochemical properties differ greatly. Thus, cPLA2 has a marked preference for arachidonic acid esterified at the sn-2 position of phospholipids and is active at submicromolar concentrations of Ca2+. In contrast, the sPLA2 does not exhibit a fatty acid preference and requires millimolar concentrations of Ca2+ for catalytic activity. Ca2+-independent PLA2 activities have also been purified and characterized, but their primary structures have not been delineated.24 25 We recently reported the localization of cPLA2 in a subset of human brain astrocytes.26 Because of the intense astrocytic activation in the hippocampus of animals subjected to global ischemia, we decided to investigate the localization of cPLA2 in the rat brain subjected to global ischemia with an antiserum recently developed that cross-reacts with rodent cPLA2.
| Materials and Methods |
|---|
|
|
|---|
Forebrains were postfixed by immersion for 24 hours in fixative and cryoprotected in 30% sucrose. Tissues were rapidly frozen in isopentane chilled with dry ice and serially sectioned in the coronal plane throughout the rostrocaudal extent of the hippocampus. Twenty-micron-thick sections were thaw-mounted onto gelatin-coated slides and stored at -70°C until evaluation. For anatomic localization of the lesioned areas, tissue sections were stained with cresyl violet for Nissl substance. Regions evaluated included coronal sections of the dorsal hippocampus. Immunocytochemistry of cPLA2 was achieved with the use of a polyclonal antiserum raised against human cPLA2 purified from a baculovirus insect cell expression system.16
Immunocytochemistry was performed with the use of the avidin-biotin peroxidase system (ABC kit, Vector Labs), and peroxidase enzymatic activity was revealed with 0.5 mg/mL 3,3'-diaminobenzidene in the presence of 0.003% H2O2 (DAB substrate kit, Vector Labs). Immunoperoxidase-stained sections were lightly counterstained with hematoxylin to delineate cytoarchitecture. To ensure accuracy when results from immunostained slides were compared, multiple sections from both 4-VO and control brains were stained in parallel on the same day. Development times in 3,3'-diaminobenzidene were held constant for all sections. These experimental conditions reduced the possibility that differences in immunoreactivity profiles might be accounted for on the basis of experimental variables (eg, antibody titer/affinity, tissue postfixation, 3,3'-diaminobenzidene development times). Quantitative immunocytochemistry with the use of image analysis was not performed on these slides because of the robust differences in specific staining between ischemic versus control animals.
The distribution of cPLA2 was compared with that of glial cells by performing immunoperoxidase staining on adjacent sections. To identify astrocytes, antisera directed to GFAP (Biogenex Labs), an intermediate filament protein unique to astrocytes,28 and a monoclonal antibody directed against the cytosolic protein S-100 (Biogenex Labs) were used. For localization of microglia, monoclonal antibodies OX42 (Bioproducts for Science) and ED1 were used. OX42 identifies the CR3 complement receptor that is expressed on activated microglia,5 29 and the antibody ED1 defines a cytosolic protein that is present within all cells of the rat monocyte/macrophage lineage.30 ED1 recognizes end-stage amoeboid microglia in the brain31 and does not stain resting microglia.32 For colocalization experiments on the same tissue section, double immunofluorescence techniques were used. Double staining was performed sequentially as follows: sections were stained first with cPLA2 antiserum, which was localized with biotin anti-rabbit followed by avidin-Texas red (Vector Labs), then with one of the above monoclonal antibodies for astrocytes or microglia. The monoclonal antibody was localized with goat anti-mouse immunoglobulins (high fluorescent conjugate, Antibodies Inc). Sections were examined with a Nikon Microphot microscope equipped with epifluorescence and Nomarski optics.
Positive and negative controls were conducted in parallel with cPLA2-stained sections or cells in each experiment. Staining of sections with commercially available antibodies served as the positive control. Negative controls included staining tissue sections with omission of the primary antibody. In addition, sections were stained with anti-cPLA2 antiserum that had been preadsorbed with an excess of cPLA2 purified from a baculovirus cell expression system.16
PLA2 activity was assayed in microdissected dorsal
hippocampal tissue excised from four sham-operated controls and
from four rats at 72 hours after 4-VO. Sonicated liposomes containing
1-palmitoyl-2-[14C]arachidonoyl-sn-glycero-3-phosphocholine
(
50 mCi/mmol; DuPont-NEN) and sn-1,2-dioleoyl glycerol
(Avanti Polar Lipids) at a molar ratio of 2:1 were prepared as
previously described.22 These liposomes are an extremely
poor substrate for the 14-kD sPLA2.33 The
assay buffer consisted of 1 mmol/L dithiothreitol, 150 mol/L NaCl, and
50 mmol/L HEPES, pH 7.5, containing 1 mg/mL of bovine serum
albumin, 1 mmol/L CaCl2, 2 µmol/L
[14C]arachidonoyl-phosphatidylcholine (50 000 dpm)/1
µmol/L dioleoyl glycerol, and incubations were performed at 37°C
for 15 minutes. To evaluate the contribution of
Ca2+-independent PLA2 activities, we included
10 mmol/L EDTA in the assay buffer. This assay system is specific for
cPLA2, as previously shown with platelets
(R.M.K. et al, unpublished data, 1993).
All procedures were performed at 4°C. Microdissected dorsal hippocampus (40 to 70 mg) was homogenized in 500 µL lysis buffer (5 mmol/L EDTA, 150 mmol/L NaCl, 25 mmol/L Tris-HCl, pH 7.5, containing 0.2 mmol/L Na3VO4, 1 mmol/L Pefabloc [Bachem], 0.06 mg/mL aprotinin, 0.05 mg/mL leupeptin, 100 nmol/L microcystin, 10.2 µmol/L pepstatin A) with the use of a Polytron homogenizer. Homogenates were briefly sonicated (ten 2-second bursts) with a Heat Systems Microson cell disrupter. The sonicates were then centrifuged for 30 minutes at 100 000g with a Sorvall RC-M120EX centrifuge. Supernatants were recovered and concentrated approximately 10-fold with Centricon 10 microconcentrators (Amicon). After volumes were adjusted to 100 µL with lysis buffer, cytosolic extracts were assayed for PLA2 activity (10 µL) and protein content (1 µL) and subjected to SDS-PAGE/immunoblotting analysis (4 µL) as detailed below.
After addition of Tricine SDS sample buffer (Novex) (twice) and dithiothreitol to a final concentration of 100 mmol/L, brain cytosolic concentrates were boiled for 5 minutes. Samples were electrophoresed in 7.5% polyacrylamide Tris-HCl gels (0.75 mm thick, Daiichi) at 50 mA for 1.3 hours at room temperature with the use of an Integrated Separation Systems apparatus and Integrated Separation Systems premixed anode buffer (200 mmol/L Tris-HCl, pH 8.9) and cathode buffer (100 mmol/L Tris-base, pH 8.25, 100 mmol/L Tricine, and 0.1% SDS). Standard proteins were Rainbow Markers (range, 14.3 to 200 kD; Amersham), human cPLA2 purified from a baculovirus/insect cell expression system, or rat platelet lysate containing cPLA2. After electrophoresis, the gel was equilibrated in electroblotting buffer (10 mmol/L 3-(cyclohexylamino)-1-propanesulfonic acid, pH 11.0, 0.01% SDS, and 1% methanol) for 5 minutes, followed by two more washes. Proteins were electroblotted onto polyvinylidene difluoride (Biorad, 0.2 µm) at 500 mA constant current and nonlimiting voltage for 1 hour at 20°C with the use of the Hoefer tank system. After the transfer, the PVDF membranes were dried, wetted in methanol and water, and incubated for 1 hour at room temperature in blocking buffer TBST (25 mmol/L Tris-HCl, pH 7.5, 137 mmol/L NaCl, 2.6 mmol/L KCl, 0.1% Tween-20, and 0.2% I-Block [Torpix]). The blots were incubated for 1 hour with rabbit anti-cPLA2 antiserum diluted 1:5000 in TBST and were washed three times quickly, followed by three more 5-minute washes in TBST. Membranes were then incubated for 30 minutes with goat anti-rabbit IgG(H+L)/horseradish peroxidase conjugate (Jackson ImmunoResearch) diluted 1:5000 into TBST and then were washed three times quickly, followed by three 5-minute washes with TBST. The blots were washed three times quickly, followed by one 5-minute wash with TBST omitting the I-Block and were then developed with the enhanced chemiluminescence detection system (Amersham). Quantitation was performed by phosphoimager analysis.
Protein measurements were made in the presence of 0.05% SDS with the use of Coomassie Plus protein reagent (Pierce), with bovine serum albumin as a reference standard.
| Results |
|---|
|
|
|---|
|
cPLA2 was selectively expressed in areas of
neurodegeneration. In the hippocampus of animals subjected to 4-VO,
cPLA2 immunoreactivity was observed in multiple layers of
the CA1 region including stratum pyramidale, stratum
radiatum, stratum oriens, and lacunosum moleculare. Other hippocampal
regions displayed relatively little staining. cPLA2
immunostaining came to an abrupt halt at the boundary
between CA1 and CA2 (Fig 1F
). This boundary precisely defines
the
region of selective neuronal degeneration. At this border zone,
intact-appearing Nissl-stained neurons of CA2 were observed
immediately adjacent to necrotic CA1 neurons that lacked Nissl
substance (Fig 1E
).
High magnification of cPLA2 immunoperoxidase-stained
sections from 4-VO brains revealed distinctive labeling of cells. The
distribution pattern appeared granular in many immunoreactive profiles
(Fig 2C
, arrows). Many stained structures resembled
morphologically identifiable astrocytes. Indeed, some immunopositive
processes were found to terminate on blood vessels, a feature unique to
these cells. Other immunopositive structures assumed a rounded amoeboid
morphology characteristic of brain macrophages.
Immunoreactivity was not detected within vascular
endothelial cells. In our experience,
endothelial cells are not a particularly prominent
source of cPLA2 and are unlikely to significantly
contribute to the observed PLA2 activity and protein
(R.M.K. et al, unpublished data, 1993). Control brains exhibited rare
cPLA2 immunoreactive cells scattered throughout the
hippocampus that were presumptive astrocytes (Fig 2A
). These
cells were
not observed at low magnification (Fig 1B
). When compared with
presumptive astrocytes detected in control brains, cPLA2
immunopositive astrocytes in 4-VO brains exhibited morphological
features consistent with an activated state, including
swollen cell bodies and enlarged processes.
|
Six animals were evaluated at 24 hours after ischemia. At this
time point, there is no histological evidence of
neuronal damage in the CA1
region.34 35 36 cPLA2
staining revealed immunoreactive astrocytes scattered throughout the
CA1 region (Fig 2B
). The intensity and number of immunopositive
cells
were significantly less than those observed at 72 hours yet more than
those observed in sham controls.
To determine the identity of the cells that contain cPLA2
immunoreactivity, double immunofluorescent staining was
performed in the hippocampus from animals subjected to 4-VO. Several
markers of both astrocytes and microglia were evaluated. In the CA1
region, cPLA2 immunopositive cells were found to colocalize
with GFAP (Fig 3A
and 3B
) and with S-100
immunoreactive
astrocytes (Fig 3C
and 3D
). Colocalization of
cPLA2
immunoreactivity with these astrocyte markers was most often observed
to be coincident in cells that could be identified as astrocytes by
their morphology alone. Not all astrocytes identified by these markers
were double labeled with cPLA2 antiserum. A distinct
population of stained cells in this region that did not exhibit
astrocyte-like morphology were immunoreactive for the microglial
cell marker OX42 (Fig 3E
and 3F
). The rounded
amoeboid-appearing
cells were most often colocalized with the macrophage marker
ED1 (Fig 3G
and 3H
). Punctate cPLA2 staining was
most often associated
with cells that also expressed the microglial markers. Only a subset of
microglia, defined by either OX42 or ED1, was positive for
cPLA2 immunoreactivity. Thus, both astrocytes and microglia
expressed cPLA2 immunoreactivity at 72 hours after
4-VO.
|
To further examine the presence of cPLA2 in rat dorsal
hippocampus, we performed assays for PLA2 activity and
subjected hippocampal extracts to immunoblotting
analysis. We found that the enzymatic activity of
cPLA2 was increased threefold in cytosolic extracts of
dorsal hippocampus from ischemic rats compared with
sham-operated control rats (Fig 4A
).
Consistent with the Ca2+ requirement of
cPLA2, this enzymatic activity was inhibited in the
presence of the chelating agent EDTA. The activity observed is due to
cPLA2 for the following reasons: the assay is performed in
the presence of dithiothreitol (known to inactivate
sPLA2) and uses sonicated liposomes consisting of
phosphatidylcholine and dioleoyl glycerol previously shown to be an
extremely poor substrate for sPLA2 (see Reference 33).
Since the activity is greatly reduced in the presence of EGTA, there
clearly is no involvement of a Ca2+-independent
PLA2.
|
We detected an approximately 100-kD major immunoreactive band
indicative of cPLA2 in cytosolic extracts subjected to
immunoblotting and probed with
anti-cPLA2 antiserum (Fig 4B
). This band comigrated
with purified human cPLA2 (purified from a baculovirus
expression system) and rat platelet cPLA2 and could not
be detected when the antiserum was preadsorbed with purified
cPLA2. It is well known that cPLA2 migrates
abnormally due to proline-rich residues within the enzyme.
Depending on the electrophoresis and gel system used, values for its
apparent molecular mass may vary between 85 and 110 kD. On a 7.5%
minigel, as used in the present study, cPLA2 typically
runs with an apparent mass of 100 kD. Lane 1 contains activated
rat platelet cPLA2 that shows slightly decreased
electrophoretic mobility due to phosphorylation; lane 9
contains cPLA2 from an ischemic animal; and lane 10
contains purified human cPLA2 (expressed in a
baculovirus/insect cell expressed system) that typically runs slower
than rat cPLA2.
| Discussion |
|---|
|
|
|---|
The results of this study demonstrate that after 30 minutes of global forebrain ischemia induced by 4-VO, cPLA2 immunoreactive glia appear throughout the CA1 region of the hippocampus.
Moreover, induction of PLA2 enzymatic activity due to cPLA2 occurred in microdissected dorsal hippocampus from ischemic animals. Immunoreactivity as well as enzymatic activity was strongly induced at 72 hours after ischemia, the time point of neurodegeneration in this region. A slight increase in cPLA2 immunoreactivity was already observed at 24 hours after 4-VO, before the onset of histologically evident neuronal cell death. cPLA2 immunoreactivity in the CA1 region colocalized with both astrocyte and microglial markers; however, only a subset of microglia and astrocytes was found to express cPLA2 immunoreactivity. cPLA2 expression in astrocytes occurred as early as 24 hours after 4-VO; few sparsely distributed resting astrocytes were found to express cPLA2 immunoreactivity in control tissue. Expression of cPLA2 in microglial cells was not observed until 72 hours after 4-VO, a time that was coincident with neuronal death. Notably, microglia are known to change their morphology from ramified to rounded or amoeboid at this time point.4 5 It has been recently proposed that microglia and macrophages may contribute to delayed neuronal cell death after ischemia.39 40 41 The demonstration that cPLA2 is expressed in reactive microglia in this model supports this hypothesis.
The observation that cPLA2 immunoreactivity is specifically localized to glia is supported by the following observations: (1) cPLA2 immunoreactivity is colocalized with GFAP, S-100, OX42, and ED1 immunoreactivities in the CA1 region after ischemia; (2) immunoadsorption with purified cPLA2 enzyme abolishes staining; and (3) cPLA2 immunoreactivity is present in human brain astrocytes.26 This latter study used a monoclonal antibody and demonstrated cPLA2-specific immunostaining in human cortical astrocytes in situ and in human astrocytomas in vitro. The fact that both the same cell type as well as the same distribution of stain was observed with two different antibodies in two different species is strong evidence that this enzyme is expressed in glia. Furthermore, the increased cPLA2 levels in dorsal hippocampal extracts, as demonstrated by Western blot analysis and cPLA2 enzyme assay, provide strong evidence that the increased cPLA2 immunoreactivity observed in glia by histochemistry is authentic cPLA2. Stimulation of endothelial cells in vitro has been shown to induce cPLA2 enzyme activity; basic fibroblast growth factor42 and the state of proliferation43 both affect activation of cPLA2 in cultured endothelial cells. In our in vivo study, there was no evidence that endothelial cell cPLA2 contributed to the enzyme reactivity by immunocytochemistry, although we cannot exclude the possibility that cPLA2 in brain capillary endothelial cells contributed to the increased enzyme activity (by cPLA2 activity measurements) and enzyme levels (observed by Western blots).
Rat cPLA2 mRNA has been recently reported to be induced in the hippocampus after 4-VO.44 With the use of in situ hybridization, a strong induction of cPLA2 mRNA was observed from 6 to 24 hours in the dentate granule cell layer after 10 minutes of ischemia, while the CA1 layer showed mRNA at moderate levels at 6 hours, modest levels at 12 hours, and virtually none at 24 hours. Although these data support our observations of an increase in cPLA2 in this model, the cell type expressing the mRNA and that expressing the protein are not identical nor in the same anatomic location. The apparent discrepancy may be due to the different durations of ischemia in the two studies (10 minutes versus 30 minutes) or the different time points evaluated after ischemia. Alternatively, this may be another example illustrating a mismatch between mRNA expression and protein localization.
Although it was reported previously that Ca2+-dependent PLA2 activities are increased in the ischemic/reperfused brain, the PLA2 activity in these studies was measured after short periods (minutes) of ischemia and reperfusion. Thus, Edgar et al45 reported that in ischemic gerbil brain the rise in PLA2 activity is transient, peaking at 1 minute, and reversible, returning to normal control levels after 5 minutes. Rordorf et al,46 on the other hand, found that in gerbil brain PLA2 activity was increased twofold after 10 minutes of common carotid occlusion followed by 10 minutes of reperfusion. Our study demonstrates that the levels of cPLA2 are increased in dorsal hippocampus from ischemic compared with control rats after 72 hours. The immunolocalization data suggest that there is increased expression of cPLA2 in selected cell types in the CA1 hippocampal region of ischemic brain. Our enzymatic and immunochemical analyses confirm that this is accompanied by an increase in the enzymatic activity of cPLA2 and the protein level of cPLA2 in cytosolic extracts of dorsal hippocampus from ischemic brain.
It is well documented that brain free fatty acids increase rapidly during ischemia, with arachidonic acid showing the most prominent relative increase.6 It was proposed that this early increase in free fatty acids may be due to the action of PLA2 and/or the combined action of phospholipase C, diacylglycerol lipase, and monoacylglycerol lipase.7 8 Notably, cPLA2 is the only PLA2 known to date that has a high preference for arachidonic acid esterified at the 2-position of phospholipids. Lipid mediators derived from products of PLA2 activity, including prostaglandins, leukotrienes, thromboxanes, and PAF,11 13 47 are also transiently increased in the brain within an hour after ischemia and reperfusion. This prominent early rise in fatty acids, eicosanoids, and PAF may be the result of the marked increase in cytosolic free [Ca2+] known to trigger the activity of phospholipases.
It is tempting to try to relate glial cPLA2 expression to neuronal degeneration. There remains the possibility that the increase in cPLA2 is a result of neuronal death. However, we do not believe this is the case because we observed an increase in immunoreactivity in astrocytes at 24 hours after ischemia, before the onset of neuronal necrosis, albeit not as intense as the response observed at 72 hours. Furthermore, we found a profound induction of cPLA2 immunoreactivity in astrocytes surrounding axotomized motor neurons after facial nerve axotomy, in which neurons never undergo necrosis (D.T.S. and J.A.C., unpublished data, 1995). If the reactive astrocytes containing cPLA2 are not induced by neuronal cell death, then perhaps they might play a role in some aspect of neuroprotection or synaptic modification. If we consider that astrocytes have profuse connections with neurons and the possibility that astrocytic neuronal signaling is mediated through intercellular connections rather than synaptically,48 it then follows that astrocytic products could have a crucial role in neuronal survival. On the other hand, several studies have implicated microglia as a class of cells that can mediate neurodegeneration by producing neurotoxins such as superoxide, nitric oxide, and other unidentified agents.
Several lines of evidence suggest that oxidative damage may underlie the mechanism triggering increased cPLA2 activity after ischemia. Toxic reactive oxygen species have long been implicated as important mediators of ischemic brain injury.49 Lipid peroxidation was reported to be increased in vulnerable brain regions in rats after transient global ischemia between 8 and 72 hours after reperfusion.14 Hyslop et al50 recently measured elevated H2O2 levels by microdialysis in vulnerable brain regions from animals subjected to global ischemia and reperfusion. H2O2 has been shown to activate the cytosolic form of PLA2 in vascular smooth muscle cells by promoting its phosphorylation.51 Under pathological conditions, oxygen radicals can be produced from arachidonate metabolism.52 Oxygen radical generation produces lipid peroxides and stimulates PLA2 activity.53 54 55 These data fit well with the hypothesis that reactive oxygen species may induce cPLA2 activity. However, at the present time it is difficult to assign a specific role for glial cPLA2 in the neurodegenerative process. It could have a neuroprotective role by producing mediators that cause the production of protective factors; more likely it could potentiate neurodegeneration by local release of agents such as lysophospholipids, eicosanoids, or PAF. Experiments evaluating the efficacy of selective cPLA2 inhibitors in this model will help address this issue.
| Selected Abbreviations and Acronyms |
|---|
|
Received June 27, 1995; revision received October 18, 1995; accepted November 8, 1995.
| References |
|---|
|
|
|---|
2. Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain global ischemia. Ann Neurol. 1982;11:491-498. [Medline] [Order article via Infotrieve]
3. Schmidt-Kastner R, Szymas J, Hossmann K-A. Immunohistochemical study of glial reaction and serum-protein extravasation in relation to neuronal damage in rat hippocampus after ischemia. Neuroscience.. 1990;38:527-540. [Medline] [Order article via Infotrieve]
4. Morioka T, Kalehua AN, Streit WJ. The microglial reaction in the rat dorsal hippocampus following transient forebrain ischemia. J Cereb Blood Flow Metab. 1991;11:966-973. [Medline] [Order article via Infotrieve]
5. Gehrmann J, Bonnekoh P, Miyazawa T, Hossman K-A, Kreutzberg GW. Immunocytochemical study of an early microglial activation in ischemia. J Cereb Blood Flow Metab. 1992;12:257-269. [Medline] [Order article via Infotrieve]
6. Rehncrona S, Westerberg E, Akesson B, Siesjo BK. Brain cortical fatty acids and phospholipids during and following complete and severe incomplete ischemia. J Neurochem. 1982;38:84-93. [Medline] [Order article via Infotrieve]
7. Yoshida S, Ikeda M, Busto R, Santiso M, Martinez E, Ginsberg M. Cerebral phophoinositide, triacylglycerol and energy metabolism in reversible ischemia: origin and fate of free fatty acids. J Neurochem. 1986;47:744-757. [Medline] [Order article via Infotrieve]
8. Abe K, Kogure K, Yamamoto H, Imazawa M, Miyamoto K. Mechanism of arachidonic acid liberation during ischemia in gerbil cerebral cortex. J Neurochem. 1987;48:503-509. [Medline] [Order article via Infotrieve]
9.
Moskowitz MA, Kiwok KJ, Hekimian K, Levine L.
Synthesis of compounds with properties of leukotrienes C4
and D4 in gerbil brains after ischemia and reperfusion.
Science. 1984;224:886-888.
10. Kiwok KJ, Moskowitz MA, Levine L. Leukotriene production in gerbil brain after ischemic insult, subarachnoid hemorrhage, and concussive injury. J Neurosurg. 1985;62:865-869. [Medline] [Order article via Infotrieve]
11.
Kempski O, Skahami E, Von Lubitz D, Hallenbeck JM,
Feuerstein G. Postischemic production of
eicosanoids in gerbil brain. Stroke. 1987;18:111-119.
12.
Usui M, Asano T, Takakura K. Identification and
quantitative analysis of hydroxy-eicosatetraenoic acids in
rat brains exposed to regional ischemia.
Stroke. 1987;18:490-494.
13. Lindsberg PJ, Hallenbeck JM, Feuerstein G. Platelet-activating factor in stroke and brain injury. Ann Neurol. 1991;30:117-129. [Medline] [Order article via Infotrieve]
14.
Bromont C, Marie C, Bralet J. Increased lipid
peroxidation in vulnerable brain regions after transient forebrain
ischemia in rats. Stroke. 1989;20:918-924.
15. Bazan NG. Arachidonic acid in the modulation of excitable membrane function and at the onset of brain damage. Ann N Y Acad Sci. 1989;559:1-16.
16.
Kramer RM, Roberts EF, Manetta JV, Hyslop PA,
Jakubowski JA. Thrombin-induced
phosphorylation and activation of
Ca2+-sensitive cytosolic phospholipase A2 in
human platelets. J Biol Chem. 1993;268:26796-26804.
17. Kramer RM. Structure and function of cytosolic phospholipase A2. In: Liscovitch M, ed. Signal-Activated Phospholipases. Austin, Tex: RG Landes Co; 1994:13-30.
18. Kimura H, Okamoto K, Sakai Y. Modulatory effects of prostaglandin D2, E2 and F2alpha on the postsynaptic actions of inhibitory and excitatory amino acids in cerebellar Purkinje cell dendrites in vitro. Brain Res. 1985;330:235-244. [Medline] [Order article via Infotrieve]
19.
Kramer RM, Hession C, Johansen B, Hayes G, McGray P,
Chow EP, Tizard R, Pepinsky RB. Structure and properties of a
human non-pancreatic phospholipase A2. J
Biol Chem. 1990;264:5768-5775.
20. Clark JD, Lin LL, Driz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N, Knopf JL. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 1991;65:1043-1051. [Medline] [Order article via Infotrieve]
21.
Clark JD, Milona N, Knopf JL. Purification of a
110-kilodalton cytosolic phospholipase A2 from the human monocytic cell
line U937. Proc Natl Acad Sci U S A. 1990;87:7708-7712.
22.
Kramer RM, Roberts EF, Manetta J, Putnam JE. The
Ca++-sensitive cytosolic phospholipase A2 is a
100-kDa protein in human monoblast U937 cells. J
Biol Chem. 1991;266:5268-5272.
23.
Sharp JD, White DL, Chiou XG, Goodson T, Gamboa GC,
McClure D, Burgett S, Hoskins J, Skatrud PL, Sportsman JR, Becker GW,
Kang LH, Roberts EF, Kramer RM. Molecular cloning and expression
of human Ca2+-sensitive cytosolic phospholipase A2.
J Biol Chem. 1991;266:14850-14853.
24.
Ackermann EJ, Kempner ES, Dennis EA.
Ca++-independent cytosolic phospholipase A2
from macrophage-like P388D1 cells. J
Biol Chem. 1994;269:9227-9233.
25. Gross RW. Myocardial phospholipases A2 and their membrane substrates. Trends Cardiovasc Med. 1992;2:115-121.
26. Stephenson DT, Manetta JV, White DL, Chiou XG, Cox L, Gitter B, May P, Sharp JD, Kramer RM, Clemens JA. Calcium-sensitive cytosolic phospholipase A2 is expressed in human brain astrocytes. Brain Res. 1994;637:97-105. [Medline] [Order article via Infotrieve]
27.
Pulsinelli WA, Brierley JB. A new model of
bilateral hemispheric ischemia in the
unanesthetized rat. Stroke. 1979;10:267-272.
28. Bignami A, Dahl D. Astrocyte-specific protein and radial glia in the cerebral cortex of newborn rat. Nature. 1974;252:55-56. [Medline] [Order article via Infotrieve]
29. Graeber MB, Tetzlaff W, Streit WJ, Kreutzberg GW. Microglial cells but not astrocytes undergo mitosis following rat facial nerve axotomy. Neurosci Lett. 1988;85:317-321. [Medline] [Order article via Infotrieve]
30. Dijkstra CD, Doepp EA, Joling P, Draal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognised by monoclonal antibodies ED1, ED2 and ED3. Immunology.. 1985;54:589-599. [Medline] [Order article via Infotrieve]
31. Flaris NA, Densmore TL, Molleston MC, Hickey WF. Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia. 1993;7:34-40. [Medline] [Order article via Infotrieve]
32. Sminia T, De Groot CJA, Dijkstra CD, Koetsier JC, Polman CH. Macrophages in the central nervous system of the rat. Immunobiology. 1987;174:43-50. [Medline] [Order article via Infotrieve]
33. Johansen B, Kramer RM, Hession C, McGray P, Pepinsky RB. Expression, purification and biochemical comparison of natural and recombinant human non-pancreatic phospholipase A2. Biochem Biophys Res Commun. 1992;187:544-551. [Medline] [Order article via Infotrieve]
34. Kirino T, Tamura A, Sano K. Delayed neuronal death in the rat hippocampus following transient forebrain ischemia. Acta Neuropathol (Berl).. 1984;64:139-147. [Medline] [Order article via Infotrieve]
35. Pulsinelli WA. Selective neuronal vulnerability: morphological and molecular characteristics. Prog Brain Res. 1985;63:29-37. [Medline] [Order article via Infotrieve]
36. Schmidt-Kastner R, Freund TF. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience. 1991;40:599-636. [Medline] [Order article via Infotrieve]
37. Ordy JM, Wengenack TM, Bialobok P, Coleman PD, Rodier P, Baggs RB, Dunlap WP, Kates B. Selective vulnerability and early progression of hippocampal CA1 pyramidal cell degeneration and GFAP-positive astrocyte reactivity in the rat four-vessel occlusion model of transient global ischemia. Exp Neurol. 1993;119:128-139. [Medline] [Order article via Infotrieve]
38. Petito CK, Halaby IA. Relationship between ischemia and ischemic neuronal necrosis to astrocyte expression of glial fibrillary acidic protein. Int J Dev Neurosci. 1993;11:239-247. [Medline] [Order article via Infotrieve]
39. Lees GJ. The possible contribution of microglia and macrophages to delayed neuronal death after ischemia. J Neurol Sci. 1993;114:119-122. [Medline] [Order article via Infotrieve]
40. Giulian D, Vaca K. Inflammatory glia mediate delayed neuronal damage after ischemia in the central nervous system. Stroke. 1993;24:I84-I90.
41. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia. 1993;7:111-118. [Medline] [Order article via Infotrieve]
42.
Sa G, Murugesan G, Jaye M, Ivashchendo Y, Fox
PL. Activation of cytosolic phospholipase A2 by basic fibroblast
growth factor via a p42 mitogen-activated protein
kinase-dependent phosphorylation pathway in
endothelial cells. J Biol
Chem. 1995;270:2360-2366.
43. Whatley RE, Satoh K, Zimmerman GA, McIntyre TM, Prescott SM. Proliferation-dependent changes in release of arachidonic acid from endothelial cells. J Clin Invest. 1994;94:1889-1900.
44. Owada Y, Tominaga T, Yoshimoto T, Kondo H. Molecular cloning of rat cDNA for cytosolic phospholipase A2 and the increased gene expression in the dentate gyrus following transient forebrain ischemia. Mol Brain Res. 1994;25:364-368. [Medline] [Order article via Infotrieve]
45. Edgar AG, Strosznajder J, Horracks LA. Activation of ethanolamine phospholipase A2 in brain during ischemia. J Neurochem. 1982;39:1111-1116. [Medline] [Order article via Infotrieve]
46. Rordorf G, Uemura Y, Bonventre JV. Characterization of phospholipase A2 activity in gerbil brain: enhanced activities of cytosolic, mitochondrial and microsomal forms after ischemia and reperfusion. J Neurosci. 1991;11:1829-1836. [Abstract]
47. Dempsey RJ, Roy MW, Meyer K, Cowen DE, Tai H-H. Development of cyclooxygenase and lipoxygenase metabolites of arachidonic acid after transient cerebral ischemia. J Neurosurg. 1986;64:118-124. [Medline] [Order article via Infotrieve]
48.
Nedergaard M. Direct signaling from astrocytes
to neurons in cultures of mammalian brain cells.
Science. 1994;263:1768-1771.
49. Panetta JA, Clemens JA. Pathophysiology of reperfusion injury in brain. In: Das DK, ed. Pathophysiology of Reperfusion Injury. Boca Raton, Fla: CRC Press, Inc; 1993:377-394.
50. Hyslop PA, Zhang Z, Pearson DV, Phebus LA. Measurement of striatal H2O2 by microdialysis following global forebrain ischemia and reperfusion in the rat: correlation with the cytotoxic potential of H2O2 in vitro. Brain Res. 1995;671:181-186. [Medline] [Order article via Infotrieve]
51. Rao GN, Runge MS, Alexander RW. Hydrogen peroxide activation of cytosolic phopholipase A2 in vascular smooth muscle cells. Biochim Biophys Acta. 1995;1265:67-72. [Medline] [Order article via Infotrieve]
52. Kontos HA. Oxygen radicals from arachidonate metabolism in abnormal vascular responses. Am Rev Respir Dis. 1987;136:474-477. [Medline] [Order article via Infotrieve]
53. Chan PH, Fishman RA. Alterations of membrane integrity and cellular constituents by arachidonic acid in neuroblastoma and glioma cells. Brain Res. 1982;248:151-157. [Medline] [Order article via Infotrieve]
54. Chan PH, Yurko M, Fishman RA. Phospholipid degradation and cellular edema induced by free radicals in brain cortical slices. J Neurochem. 1982;38:525-531. [Medline] [Order article via Infotrieve]
55. Au AM, Chan PH, Fishman RA. Stimulation of phospholipase A2 activity by oxygen-derived free radicals in isolated brain capillaries. J Cell Biochem. 1985;27:449-453.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
G. N. Neigh, K. Karelina, E. R. Glasper, S. L.K. Bowers, N. Zhang, P. G. Popovich, and A. C. DeVries Anxiety After Cardiac Arrest/Cardiopulmonary Resuscitation: Exacerbated by Stress and Prevented by Minocycline Stroke, November 1, 2009; 40(11): 3601 - 3607. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Farooqui, W.-Y. Ong, and L. A. Horrocks Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders Pharmacol. Rev., September 1, 2006; 58(3): 591 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Adibhatla, J. F. Hatcher, E. C. Larsen, X. Chen, D. Sun, and F. H. C. Tsao CDP-choline Significantly Restores Phosphatidylcholine Levels by Differentially Affecting Phospholipase A2 and CTP: Phosphocholine Cytidylyltransferase after Stroke J. Biol. Chem., March 10, 2006; 281(10): 6718 - 6725. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. del Zoppo, K. J. Becker, and J. M. Hallenbeck Inflammation After Stroke: Is It Harmful? Arch Neurol, April 1, 2001; 58(4): 669 - 672. [Full Text] [PDF] |
||||
![]() |
A. A. Farooqui, W. Y. Ong, L. A. Horrocks, and T. Farooqui Brain Cytosolic Phospholipase A2: Localization, Role, and Involvement in Neurological Diseases Neuroscientist, June 1, 2000; 6(3): 169 - 180. [Abstract] [PDF] |
||||
![]() |
R. K. K. Lee, S. Knapp, and R. J. Wurtman Prostaglandin E2 Stimulates Amyloid Precursor Protein Gene Expression: Inhibition by Immunosuppressants J. Neurosci., February 1, 1999; 19(3): 940 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Clemens, D. T. Stephenson, T. Yin, E. B. Smalstig, J. A. Panetta, S. P. Little, W. D. Dietrich, and J. Bethea Drug-Induced Neuroprotection From Global Ischemia Is Associated With Prevention of Persistent but Not Transient Activation of Nuclear Factor-{kappa}B in Rats • Editorial Comment Stroke, March 1, 1998; 29(3): 677 - 682. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Clemens, D. T. Stephenson, E. B. Smalstig, E. P. Dixon, and S. P. Little Global Ischemia Activates Nuclear Factor-{kappa}B in Forebrain Neurons of Rats Stroke, May 1, 1997; 28(5): 1073 - 1081. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |